Skip to main content
BioLineRx Ltd. logo

BioLineRx Ltd. — Investor Relations & Filings

Ticker · BLRX ISIN · US09071M2052 LEI · 529900AKIOSC15Y63R18 TA Manufacturing
Open in API
Filings indexed 1,671 across all filing types
Latest filing 2025-03-31 Earnings Release
Country IL Israel
Listing TA BLRX

About BioLineRx Ltd.

https://www.biolinerx.com/

BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for oncology and rare diseases. The company leverages its drug development capabilities to advance novel, early-stage therapeutic candidates through the clinical development process toward regulatory approval. Its pipeline consists of treatments, including small molecules, designed to address unmet medical needs and deliver meaningful benefits to patients. BioLineRx also partners with other drug developers to advance their early-stage programs.

Recent filings

Filing Released Lang Actions
BioLineRx Reports 2024 Financial Results and Provides Corporate Update
Earnings Release Classification · 95% confidence The document is a Form 6-K filing from BioLineRx Ltd. which contains a press release announcing the company's 2024 financial results. While it contains financial data, it is an announcement of the results and explicitly states that the full annual report (Form 20-F) has been filed separately with the SEC. According to the 'Menu vs Meal' rule, this is an announcement of a report rather than the full annual report itself. Therefore, it is classified as an Earnings Release (ER) as it focuses on the initial announcement of financial results and corporate updates. FY 2024
2025-03-31 English
BioLineRx Reports 2024 Financial Results and Provides Corporate Update
Report Publication Announcement Classification · 100% confidence The document is a short notification (1889 characters) from BioLine Rx Ltd regarding the publication of their 'Annual Report on Form 20-F'. It explicitly states 'Attached hereto is a report on Annual Report on Form 20-F' and provides a filename for the attachment. Per the 'MENU VS MEAL' rule, since this is an announcement of a report rather than the report itself, it is classified as a Report Publication Announcement (RPA). FY 2024
2025-03-31 English
6-K
Foreign Filer Report
2025-03-31 English
20-F
Annual Report FY 2024
2025-03-31 English
Letter to Shareholders
Management Reports Classification · 95% confidence The document is explicitly titled 'FORM 6-K' and is filed with the 'SECURITIES AND EXCHANGE COMMISSION' as a 'REPORT OF FOREIGN PRIVATE ISSUER'. This form is typically used for current reports that are not required to be filed on a regular schedule (like 10-K or 10-Q). The content is a 'Letter to Shareholders' from the CEO outlining strategic vision, financial outlook, recent licensing deals (Ayrmid, GloriaBio), balance sheet strength, and a planned ADS ratio change. This content strongly aligns with an Earnings Release (ER) or Management Discussion & Analysis (MDA) in terms of substance, but the filing vehicle is Form 6-K. Since the document contains the CEO's detailed explanation of financial results, business trends, and outlook following recent events, it functions as a comprehensive management report accompanying the required regulatory filing. Given the options, 'Management Reports' (MDA) captures the narrative content best, even though the wrapper is a 6-K. However, Form 6-K is a general current report. If the content were purely a brief announcement of results, ER would fit. Since it is a detailed letter explaining strategy and financials, MDA is appropriate. Alternatively, since it is a Form 6-K, which is a general current report, and the content is a detailed letter to shareholders, it is often classified under the general regulatory filing category if MDA is too specific for the wrapper. Given the detailed strategic and financial commentary, MDA is the most accurate functional classification. If MDA were not available, RNS (Regulatory Filings) would be the fallback for a Form 6-K. I will select MDA based on the detailed narrative content.
2025-01-21 English
Letter to Shareholders
Report Publication Announcement Classification · 98% confidence The document is very short (1780 characters) and explicitly states, "Attached hereto is a report on *Letter to Shareholders* *Form_6-k_21-Jan-25_isa.pdf*". This structure indicates that the document itself is an announcement about the availability of another report (the Letter to Shareholders), rather than the full content of that report. According to Rule 2, when a document is short and announces the publication of another report, it should be classified as a Report Publication Announcement (RPA). Although 'Letter to Shareholders' might suggest an Annual Report (10-K) or Investor Presentation (IP), the format here is purely an announcement wrapper, fitting the RPA definition best.
2025-01-21 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.